LitCovid-sentences  

PMC:7324763 / 38412-43287 JSONTXT 13 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T214 0-133 Sentence denotes Category Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)
T215 134-156 Sentence denotes NK cell-based products
T216 157-270 Sentence denotes       Adoptive NK cells NK cells NCT04280224 I Henan, China 30 Pneumatic COVID19+ Adoptive NK cell therapy
T217 271-389 Sentence denotes CYNK-001 NCT04365101 I/II New Jersey, USA 86 Mild COVID19+ From human placental CD34+ cells and culture-expanded
T218 390-543 Sentence denotes NK cells isolated from healthy donor PBMCs NCT04344548 I/II Bagota, Colombia 10 NEWS of >4 Isolated NK cells ex vivo stimulated with IL-2 and IL-15
T219 544-872 Sentence denotes       CAR-NK Cells NKG2D-ACE2 CAR-NK cell therapy from umbilical cord blood NCT04324996 I/II Chongqing, China 90 Within <14 dpi IL-15 prolongs NK cell lifespan; GM-CSF neutralizing scFV reduces recruitment of inflammatory cells; NKG2D-ACE2 CAR-NK cells can target virally infected cells; ACE2 CAR-NK can act as decoy cell
T220 873-897 Sentence denotes NK cell immunostimulants
T221 898-923 Sentence denotes Direct NK cell activation
T222 924-1157 Sentence denotes       IFN-α Therapy Recombinant human IFN-α ± Thymosin alpha 1 NCT04320238 III Hubei, China 2,944 Uninfected HCW IFN-alpha boosts immune system; thymosin alpha 1 activates TLRs in myeloid and pDCs leading to NK cell activation
T223 1158-1273 Sentence denotes Recombinant human IFN-α2β NCT04293887 I Hubei, China 328 Within <7 dpi IFN-alpha activates interferon pathway
T224 1274-1383 Sentence denotes Abidol Hydrochloride ± IFN atomization (Peg-IFN-α-2b) NCT04254874 IV Hubei, China 100 Pneumatic COVID19+
T225 1384-1483 Sentence denotes Rintatolimod ± Recombinant IFN-α2β NCT04379518 I/II New York, USA 80 Mild to moderate COVID19+
T226 1484-1628 Sentence denotes       IFN-β Therapy Lopinavir/ritonavir ± IFN-β-1a NCT04315948 III France (3) 3,100 Moderate/Severe IFN-beta activates interferon pathway
T227 1629-1761 Sentence denotes Base therapy ± IFN-β-1a NCT04350671 IV Tehran, Iran 40 Within <10 dpi Base therapy = Hydropinchloroquine + Lopinavir/Ritonavir
T228 1762-1880 Sentence denotes Base therapy ± IFN-β-1b NCT04276688 II Hong Kong, HK 127 NEWS of ≥1 Base therapy = Lopinavir/ritonavir/Ribavirin
T229 1881-2028 Sentence denotes IFN-β-1a vs. IFN-β-1b (+Base therapy) NCT04343768 IV Tehran, Iran 60 Moderate/Severe Base therapy = Hydropinchloroquine + Lopinavir/Ritonavir
T230 2029-2056 Sentence denotes Indirect NK cell activation
T231 2057-2248 Sentence denotes       IFN-λ Therapy Peg-IFN-Lambda-1a NCT04331899 II California, USA 120 Early COVID19+ IFN-lambda to boost NK cells indirectly through Monocytes, Macrophages, and pDCs IL-12 secretion
T232 2249-2316 Sentence denotes Peg-IFN-Lambda-1a NCT04343976 II Boston, USA 40 Early COVID19+
T233 2317-2402 Sentence denotes Peg-IFN-Lambda-1a NCT04354259 II Toronto, Canada 140 Ambulatory and hospitalized
T234 2403-2474 Sentence denotes Peg-IFN-Lambda-1a NCT04388709 II New York, USA 66 Non-ICU COVID19+
T235 2475-2552 Sentence denotes Peg-IFN-Lambda-1a NCT04344600 II Maryland, USA 164 Asymptomatic COVID19+
T236 2553-2579 Sentence denotes Immunoregulatory therapies
T237 2580-2807 Sentence denotes Immune checkpoint blockade Anti-PD-1 (vs. Thymosin) NCT04268537 II Nanjing, China 120 Respiratory failure within <48h of ICU Prevent T-cell regulation by blocking PD-1; in COVID19+ advanced or metastatic cancer patients;
T238 2808-2930 Sentence denotes Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R
T239 2931-3042 Sentence denotes Anti-PD-1 (nivolumab) vs. GNS651 NCT04333914 II France (4) 273 Early COVID19+ GNS651 = Chloroquine analog
T240 3043-3081 Sentence denotes Non-specific innate immune stimulation
T241 3082-3258 Sentence denotes       Heterologous vaccines BCG NCT04328441 III Netherlands (9) 1,500 Uninfected HCW Trains and primes innate immunity against subsequent non-specific pathogen infection
T242 3259-3334 Sentence denotes BCG (Danish strain) NCT04327206 III Australia (8) 4,170 Uninfected HCW
T243 3335-3400 Sentence denotes BCG (Danish strain) NCT04350931 III Egypt 900 Uninfected HCW
T244 3401-3462 Sentence denotes BCG (Danish strain) NCT04379336 III South Africa 500 HCW
T245 3463-3527 Sentence denotes BCG (Tice strain) NCT04348370 IV USA (5) 700 Uninfected HCW
T246 3528-3590 Sentence denotes BCG NCT04369794 IV São Paulo, Brazil 1,000 Early COVID19+
T247 3591-3743 Sentence denotes       TLR agonists PUL-042 (CpG ODN) NCT04313023 II Not listed 200 Unifected/asymptomatic Activates TLR2/6/9 leading to innate immune stimulation
T248 3744-3810 Sentence denotes PUL-042 (CpG ODN) NCT04312997 II Texas, USA 100 Within <7 dpi
T249 3811-3860 Sentence denotes Natural health products and alternative medicines
T250 3861-4022 Sentence denotes       Vitamins Vitamin C NCT04323514 N/A Palermo, Italy 500 Pneumatic COVID19+ General immune boosting properties of vitamin C and natural health products
T251 4023-4082 Sentence denotes Vitamin C NCT04264533 II Hubei, China 140 ICU COVID19+
T252 4083-4145 Sentence denotes Vitamin C NCT03680274 III Quebec, Canada 800 ICU COVID19+
T253 4146-4206 Sentence denotes Vitamin C NCT04344184 II Virginia, USA 200 ICU COVID19+
T254 4207-4278 Sentence denotes Vitamin C + Zinc NCT04342728 N/A Ohio, USA 520 Outpatient COVID19+
T255 4279-4394 Sentence denotes Hydroxychloroquine; Azithromycin; Vitamin C, D; and Zinc NCT04334512 II California, USA 600 Low risk COVID-19+
T256 4395-4492 Sentence denotes Hydroxychloroquine; vitamin C, D; and Zinc NCT04335084 II California, USA 600 Uninfected HCW
T257 4493-4627 Sentence denotes Vitamin D NCT04334005 N/A Spain (2) 200 Non-severe COVID19+ Vitamin D is immunomodulatory and prevents nutritional deficiencies.
T258 4628-4798 Sentence denotes Zinc + Vitamin D (cholecalciferol) NCT04351490 N/A Lille, France 3,140 Asymptomatic COVID19+ To treat zinc and vitamin D deficiency and reduce inflammation and ARDS
T259 4799-4875 Sentence denotes High dose Vitamin D (4X) NCT04344041 III France (9) 260 Severe COVID19+